{"transactions":[{"id":1745531,"issuer":{"id":5687,"kind":"organization","name":"Lexeo Therapeutics, Inc.","symbol":"LXEO"},"owners":[{"id":108415,"kind":"person","name":"Lundbeckfond Invest A/S","position":1,"cik":"0001591046","reported_name":"Lundbeckfond Invest A/S","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B convertible preferred stock","published_at":"2023-11-10T01:33:54.000Z","date":"2023-11-07","kind":"exercise","planned":false,"acquired":false,"shares":2615533,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Upon the closing of the Issuer's initial public offering, each share of Series B convertible preferred stock automatically converted into shares of the Issuer's common stock on a one-for-9.106601 basis, which reflects an anti-dilution adjustment to the conversion ratio pursuant to a provision of the Series B convertible preferred stock based on the pricing of the initial public offering (as described in the Reporting Person's Form 3). The shares had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Upon the closing of the Issuer's initial public offering, each share of Series B convertible preferred stock automatically converted into shares of the Issuer's common stock on a one-for-9.106601 basis, which reflects an anti-dilution adjustment to the conversion ratio pursuant to a provision of the Series B convertible preferred stock based on the pricing of the initial public offering (as described in the Reporting Person's Form 3). The shares had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Upon the closing of the Issuer's initial public offering, each share of Series B convertible preferred stock automatically converted into shares of the Issuer's common stock on a one-for-9.106601 basis, which reflects an anti-dilution adjustment to the conversion ratio pursuant to a provision of the Series B convertible preferred stock based on the pricing of the initial public offering (as described in the Reporting Person's Form 3). The shares had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Upon the closing of the Issuer's initial public offering, each share of Series B convertible preferred stock automatically converted into shares of the Issuer's common stock on a one-for-9.106601 basis, which reflects an anti-dilution adjustment to the conversion ratio pursuant to a provision of the Series B convertible preferred stock based on the pricing of the initial public offering (as described in the Reporting Person's Form 3). The shares had no expiration date."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":287213},"source":{"system":"sec-edgar","filing":"0001209191-23-054907","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1591046/000120919123054907/doc4.xml","form_type":"4"}},{"id":1745530,"issuer":{"id":5687,"kind":"organization","name":"Lexeo Therapeutics, Inc.","symbol":"LXEO"},"owners":[{"id":108415,"kind":"person","name":"Lundbeckfond Invest A/S","position":1,"cik":"0001591046","reported_name":"Lundbeckfond Invest A/S","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A convertible preferred stock","published_at":"2023-11-10T01:33:54.000Z","date":"2023-11-07","kind":"exercise","planned":false,"acquired":false,"shares":13999999,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Upon the closing of the Issuer's initial public offering, each share of Series A convertible preferred stock automatically converted into shares of the Issuer's common stock on a one-for-10.594230 basis. The shares had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Upon the closing of the Issuer's initial public offering, each share of Series A convertible preferred stock automatically converted into shares of the Issuer's common stock on a one-for-10.594230 basis. The shares had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Upon the closing of the Issuer's initial public offering, each share of Series A convertible preferred stock automatically converted into shares of the Issuer's common stock on a one-for-10.594230 basis. The shares had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Upon the closing of the Issuer's initial public offering, each share of Series A convertible preferred stock automatically converted into shares of the Issuer's common stock on a one-for-10.594230 basis. The shares had no expiration date."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1321474},"source":{"system":"sec-edgar","filing":"0001209191-23-054907","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1591046/000120919123054907/doc4.xml","form_type":"4"}},{"id":1745529,"issuer":{"id":5687,"kind":"organization","name":"Lexeo Therapeutics, Inc.","symbol":"LXEO"},"owners":[{"id":108415,"kind":"person","name":"Lundbeckfond Invest A/S","position":1,"cik":"0001591046","reported_name":"Lundbeckfond Invest A/S","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-11-10T01:33:54.000Z","date":"2023-11-07","kind":"purchase","planned":false,"acquired":true,"shares":227272,"price":11,"value":2499992.0,"ownership":{"direct":true},"balance_after":1835959,"source":{"system":"sec-edgar","filing":"0001209191-23-054907","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1591046/000120919123054907/doc4.xml","form_type":"4"}},{"id":1745528,"issuer":{"id":5687,"kind":"organization","name":"Lexeo Therapeutics, Inc.","symbol":"LXEO"},"owners":[{"id":108415,"kind":"person","name":"Lundbeckfond Invest A/S","position":1,"cik":"0001591046","reported_name":"Lundbeckfond Invest A/S","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-11-10T01:33:54.000Z","date":"2023-11-07","kind":"exercise","planned":false,"acquired":true,"shares":287213,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Upon the closing of the Issuer's initial public offering, each share of Series B convertible preferred stock automatically converted into shares of the Issuer's common stock on a one-for-9.106601 basis, which reflects an anti-dilution adjustment to the conversion ratio pursuant to a provision of the Series B convertible preferred stock based on the pricing of the initial public offering (as described in the Reporting Person's Form 3). The shares had no expiration date."}],"balance_after":1608687,"source":{"system":"sec-edgar","filing":"0001209191-23-054907","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1591046/000120919123054907/doc4.xml","form_type":"4"}},{"id":1745527,"issuer":{"id":5687,"kind":"organization","name":"Lexeo Therapeutics, Inc.","symbol":"LXEO"},"owners":[{"id":108415,"kind":"person","name":"Lundbeckfond Invest A/S","position":1,"cik":"0001591046","reported_name":"Lundbeckfond Invest A/S","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-11-10T01:33:54.000Z","date":"2023-11-07","kind":"exercise","planned":false,"acquired":true,"shares":1321474,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Upon the closing of the Issuer's initial public offering, each share of Series A convertible preferred stock automatically converted into shares of the Issuer's common stock on a one-for-10.594230 basis. The shares had no expiration date."}],"balance_after":1321474,"source":{"system":"sec-edgar","filing":"0001209191-23-054907","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1591046/000120919123054907/doc4.xml","form_type":"4"}},{"id":1810033,"issuer":{"id":8764,"kind":"organization","name":"IO Biotech, Inc."},"owners":[{"id":108415,"kind":"person","name":"Lundbeckfond Invest A/S","position":1,"cik":"0001591046","reported_name":"Lundbeckfond Invest A/S","relationship":{"director":true,"ten_percent_owner":true}}],"security":"Warrants (Right to Buy)","published_at":"2023-08-12T01:22:20.000Z","date":"2023-08-09","kind":"grant","planned":false,"acquired":true,"shares":7901234,"price":0.125,"value":987654.25,"ownership":{"direct":true},"footnotes":[{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"These warrants expire at 5:00 p.m. Eastern time on the earlier of (i) February 9, 2027, and (ii) one day prior to the closing of an Acquisition (as such term is defined in the Form of Warrant, attached as Exhibit 4.1 to the Issuer's Current Report on Form 8-K, filed with the Securities and Exchange Commission on August 7, 2023)."}],"balance_after":7901234,"derivative":{"exercise_price":2.47,"exercise_date":"2023-08-09","underlying":"Common Stock","underlying_shares":7901234},"source":{"system":"sec-edgar","filing":"0001140361-23-039344","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1865494/000114036123039344/form4.xml","form_type":"4"}},{"id":1810032,"issuer":{"id":8764,"kind":"organization","name":"IO Biotech, Inc."},"owners":[{"id":108415,"kind":"person","name":"Lundbeckfond Invest A/S","position":1,"cik":"0001591046","reported_name":"Lundbeckfond Invest A/S","relationship":{"director":true,"ten_percent_owner":true}}],"security":"Common Stock","published_at":"2023-08-12T01:22:20.000Z","date":"2023-08-09","kind":"grant","planned":false,"acquired":true,"shares":7901234,"price":1.9,"value":15012344.6,"ownership":{"direct":true},"balance_after":13950686,"source":{"system":"sec-edgar","filing":"0001140361-23-039344","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1865494/000114036123039344/form4.xml","form_type":"4"}},{"id":2515542,"issuer":{"id":8764,"kind":"organization","name":"IO Biotech, Inc."},"owners":[{"id":108415,"kind":"person","name":"Lundbeckfond Invest A/S","position":1,"cik":"0001591046","reported_name":"Lundbeckfond Invest A/S","relationship":{"ten_percent_owner":true}}],"security":"Series C Preferred Stock","published_at":"2021-11-12T21:15:46.000Z","date":"2021-11-09","kind":"exercise","acquired":false,"shares":150534,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Upon the closing of the IPO, each share of Series C Preferred Stock beneficially owned by the reporting person automatically converted, for no additional consideration, into the number of shares of Common Stock reported in Column 7 of Table II. These shares of Series C Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Upon the closing of the IPO, each share of Series C Preferred Stock beneficially owned by the reporting person automatically converted, for no additional consideration, into the number of shares of Common Stock reported in Column 7 of Table II. These shares of Series C Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Upon the closing of the IPO, each share of Series C Preferred Stock beneficially owned by the reporting person automatically converted, for no additional consideration, into the number of shares of Common Stock reported in Column 7 of Table II. These shares of Series C Preferred Stock had no expiration date."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1892434},"source":{"system":"sec-edgar","filing":"0001140361-21-037653","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1865494/000114036121037653/form4.xml","form_type":"4"}},{"id":2515541,"issuer":{"id":8764,"kind":"organization","name":"IO Biotech, Inc."},"owners":[{"id":108415,"kind":"person","name":"Lundbeckfond Invest A/S","position":1,"cik":"0001591046","reported_name":"Lundbeckfond Invest A/S","relationship":{"ten_percent_owner":true}}],"security":"Series B Preferred Stock","published_at":"2021-11-12T21:15:46.000Z","date":"2021-11-09","kind":"exercise","acquired":false,"shares":219595,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Upon the closing of the Issuer's initial public offering (\"IPO\"), each share of Series B Preferred Stock beneficially owned by the reporting person automatically converted, for no additional consideration, into the number of shares of Common Stock reported in Column 7 of Table II. These shares of Series B Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Upon the closing of the Issuer's initial public offering (\"IPO\"), each share of Series B Preferred Stock beneficially owned by the reporting person automatically converted, for no additional consideration, into the number of shares of Common Stock reported in Column 7 of Table II. These shares of Series B Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Upon the closing of the Issuer's initial public offering (\"IPO\"), each share of Series B Preferred Stock beneficially owned by the reporting person automatically converted, for no additional consideration, into the number of shares of Common Stock reported in Column 7 of Table II. These shares of Series B Preferred Stock had no expiration date."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":2014161},"source":{"system":"sec-edgar","filing":"0001140361-21-037653","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1865494/000114036121037653/form4.xml","form_type":"4"}},{"id":2515540,"issuer":{"id":8764,"kind":"organization","name":"IO Biotech, Inc."},"owners":[{"id":108415,"kind":"person","name":"Lundbeckfond Invest A/S","position":1,"cik":"0001591046","reported_name":"Lundbeckfond Invest A/S","relationship":{"ten_percent_owner":true}}],"security":"Common Stock","published_at":"2021-11-12T21:15:46.000Z","date":"2021-11-09","kind":"purchase","acquired":true,"shares":2142857,"price":14,"value":29999998.0,"ownership":{"direct":true},"balance_after":6049452,"source":{"system":"sec-edgar","filing":"0001140361-21-037653","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1865494/000114036121037653/form4.xml","form_type":"4"}},{"id":2515539,"issuer":{"id":8764,"kind":"organization","name":"IO Biotech, Inc."},"owners":[{"id":108415,"kind":"person","name":"Lundbeckfond Invest A/S","position":1,"cik":"0001591046","reported_name":"Lundbeckfond Invest A/S","relationship":{"ten_percent_owner":true}}],"security":"Common Stock","published_at":"2021-11-12T21:15:46.000Z","date":"2021-11-09","kind":"exercise","acquired":true,"shares":1892434,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Upon the closing of the IPO, each share of Series C Preferred Stock beneficially owned by the reporting person automatically converted, for no additional consideration, into the number of shares of Common Stock reported in Column 7 of Table II. These shares of Series C Preferred Stock had no expiration date."}],"balance_after":3906595,"source":{"system":"sec-edgar","filing":"0001140361-21-037653","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1865494/000114036121037653/form4.xml","form_type":"4"}},{"id":2515538,"issuer":{"id":8764,"kind":"organization","name":"IO Biotech, Inc."},"owners":[{"id":108415,"kind":"person","name":"Lundbeckfond Invest A/S","position":1,"cik":"0001591046","reported_name":"Lundbeckfond Invest A/S","relationship":{"ten_percent_owner":true}}],"security":"Common Stock","published_at":"2021-11-12T21:15:46.000Z","date":"2021-11-09","kind":"exercise","acquired":true,"shares":2014161,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Upon the closing of the Issuer's initial public offering (\"IPO\"), each share of Series B Preferred Stock beneficially owned by the reporting person automatically converted, for no additional consideration, into the number of shares of Common Stock reported in Column 7 of Table II. These shares of Series B Preferred Stock had no expiration date."}],"balance_after":2014161,"source":{"system":"sec-edgar","filing":"0001140361-21-037653","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1865494/000114036121037653/form4.xml","form_type":"4"}},{"id":3208910,"issuer":{"id":4024,"kind":"organization","name":"Enliven Therapeutics, Inc.","symbol":"ELVN"},"owners":[{"id":108415,"kind":"person","name":"Lundbeckfond Invest A/S","position":1,"cik":"0001591046","reported_name":"Lundbeckfond Invest A/S","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Preferred Stock","published_at":"2020-03-16T21:07:19.000Z","date":"2020-03-16","kind":"exercise","acquired":false,"shares":1894444,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"On March 16, 2020, the Series B Preferred Stock converted into Common Stock on a 6.299-for-1 basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series B Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"On March 16, 2020, the Series B Preferred Stock converted into Common Stock on a 6.299-for-1 basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series B Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"On March 16, 2020, the Series B Preferred Stock converted into Common Stock on a 6.299-for-1 basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series B Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":300752},"source":{"system":"sec-edgar","filing":"0000899243-20-008479","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1672619/000089924320008479/doc4.xml","form_type":"4"}},{"id":3208909,"issuer":{"id":4024,"kind":"organization","name":"Enliven Therapeutics, Inc.","symbol":"ELVN"},"owners":[{"id":108415,"kind":"person","name":"Lundbeckfond Invest A/S","position":1,"cik":"0001591046","reported_name":"Lundbeckfond Invest A/S","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Preferred Stock","published_at":"2020-03-16T21:07:19.000Z","date":"2020-03-16","kind":"exercise","acquired":false,"shares":5470492,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"On March 16, 2020, Series A Preferred Stock converted into Common Stock on a 6.299-for-1 basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"On March 16, 2020, Series A Preferred Stock converted into Common Stock on a 6.299-for-1 basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"On March 16, 2020, Series A Preferred Stock converted into Common Stock on a 6.299-for-1 basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":868467},"source":{"system":"sec-edgar","filing":"0000899243-20-008479","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1672619/000089924320008479/doc4.xml","form_type":"4"}},{"id":3208908,"issuer":{"id":4024,"kind":"organization","name":"Enliven Therapeutics, Inc.","symbol":"ELVN"},"owners":[{"id":108415,"kind":"person","name":"Lundbeckfond Invest A/S","position":1,"cik":"0001591046","reported_name":"Lundbeckfond Invest A/S","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series Seed Preferred Stock","published_at":"2020-03-16T21:07:19.000Z","date":"2020-03-16","kind":"exercise","acquired":false,"shares":478749,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"On March 16, 2020, the Series Seed Preferred Stock converted into Common Stock on a 6.299-for-1 basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series Seed Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On March 16, 2020, the Series Seed Preferred Stock converted into Common Stock on a 6.299-for-1 basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series Seed Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"On March 16, 2020, the Series Seed Preferred Stock converted into Common Stock on a 6.299-for-1 basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series Seed Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":76003},"source":{"system":"sec-edgar","filing":"0000899243-20-008479","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1672619/000089924320008479/doc4.xml","form_type":"4"}},{"id":3208907,"issuer":{"id":4024,"kind":"organization","name":"Enliven Therapeutics, Inc.","symbol":"ELVN"},"owners":[{"id":108415,"kind":"person","name":"Lundbeckfond Invest A/S","position":1,"cik":"0001591046","reported_name":"Lundbeckfond Invest A/S","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-03-16T21:07:19.000Z","date":"2020-03-16","kind":"purchase","acquired":true,"shares":187500,"price":16,"value":3000000.0,"ownership":{"direct":true},"balance_after":1432722,"source":{"system":"sec-edgar","filing":"0000899243-20-008479","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1672619/000089924320008479/doc4.xml","form_type":"4"}},{"id":3208906,"issuer":{"id":4024,"kind":"organization","name":"Enliven Therapeutics, Inc.","symbol":"ELVN"},"owners":[{"id":108415,"kind":"person","name":"Lundbeckfond Invest A/S","position":1,"cik":"0001591046","reported_name":"Lundbeckfond Invest A/S","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-03-16T21:07:19.000Z","date":"2020-03-16","kind":"exercise","acquired":true,"shares":1245222,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On March 16, 2020, the Series Seed Preferred Stock converted into Common Stock on a 6.299-for-1 basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series Seed Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date."}],"balance_after":1245222,"source":{"system":"sec-edgar","filing":"0000899243-20-008479","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1672619/000089924320008479/doc4.xml","form_type":"4"}},{"id":3529261,"issuer":{"id":4387,"kind":"organization","name":"Trevi Therapeutics, Inc.","symbol":"TRVI"},"owners":[{"id":108415,"kind":"person","name":"Lundbeckfond Invest A/S","position":1,"cik":"0001591046","reported_name":"Lundbeckfond Invest A/S","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series C Preferred Stock","published_at":"2019-05-13T21:00:35.000Z","date":"2019-05-09","kind":"exercise","acquired":false,"shares":6849315,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"On May 9, 2019, the Series C Preferred Stock, and the dividends that had accrued thereon to date, converted into Common Stock on a 9.5-for-one basis without payment of further consideration automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On May 9, 2019, the Series C Preferred Stock, and the dividends that had accrued thereon to date, converted into Common Stock on a 9.5-for-one basis without payment of further consideration automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"On May 9, 2019, the Series C Preferred Stock, and the dividends that had accrued thereon to date, converted into Common Stock on a 9.5-for-one basis without payment of further consideration automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":776544},"source":{"system":"sec-edgar","filing":"0000899243-19-013250","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1563880/000089924319013250/doc4.xml","form_type":"4"}},{"id":3529260,"issuer":{"id":4387,"kind":"organization","name":"Trevi Therapeutics, Inc.","symbol":"TRVI"},"owners":[{"id":108415,"kind":"person","name":"Lundbeckfond Invest A/S","position":1,"cik":"0001591046","reported_name":"Lundbeckfond Invest A/S","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2019-05-13T21:00:35.000Z","date":"2019-05-09","kind":"purchase","acquired":true,"shares":375000,"price":10,"value":3750000.0,"ownership":{"direct":true},"balance_after":1151544,"source":{"system":"sec-edgar","filing":"0000899243-19-013250","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1563880/000089924319013250/doc4.xml","form_type":"4"}},{"id":3529259,"issuer":{"id":4387,"kind":"organization","name":"Trevi Therapeutics, Inc.","symbol":"TRVI"},"owners":[{"id":108415,"kind":"person","name":"Lundbeckfond Invest A/S","position":1,"cik":"0001591046","reported_name":"Lundbeckfond Invest A/S","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2019-05-13T21:00:35.000Z","date":"2019-05-09","kind":"exercise","acquired":true,"shares":776544,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On May 9, 2019, the Series C Preferred Stock, and the dividends that had accrued thereon to date, converted into Common Stock on a 9.5-for-one basis without payment of further consideration automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date."}],"balance_after":776544,"source":{"system":"sec-edgar","filing":"0000899243-19-013250","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1563880/000089924319013250/doc4.xml","form_type":"4"}},{"id":4154343,"issuer":{"id":74456,"kind":"organization","name":"scPharmaceuticals Inc.","symbol":"SCPH"},"owners":[{"id":108415,"kind":"person","name":"Lundbeckfond Invest A/S","position":1,"cik":"0001591046","reported_name":"Lundbeckfond Invest A/S","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Preferred Stock","published_at":"2017-11-21T19:24:34.000Z","date":"2017-11-21","kind":"exercise","acquired":false,"shares":7067945,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"All series of Convertible Preferred Stock automatically converted into the Issuer's Common Stock on a 7.180193-for-1 basis upon on November 21, 2017 and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"All series of Convertible Preferred Stock automatically converted into the Issuer's Common Stock on a 7.180193-for-1 basis upon on November 21, 2017 and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"All series of Convertible Preferred Stock automatically converted into the Issuer's Common Stock on a 7.180193-for-1 basis upon on November 21, 2017 and had no expiration date."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F3","text":"All series of Convertible Preferred Stock automatically converted into the Issuer's Common Stock on a 7.180193-for-1 basis upon on November 21, 2017 and had no expiration date."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":984366},"source":{"system":"sec-edgar","filing":"0000899243-17-027197","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1604950/000089924317027197/doc4.xml","form_type":"4"}},{"id":4154342,"issuer":{"id":74456,"kind":"organization","name":"scPharmaceuticals Inc.","symbol":"SCPH"},"owners":[{"id":108415,"kind":"person","name":"Lundbeckfond Invest A/S","position":1,"cik":"0001591046","reported_name":"Lundbeckfond Invest A/S","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Preferred Stock","published_at":"2017-11-21T19:24:34.000Z","date":"2017-11-21","kind":"exercise","acquired":false,"shares":11092383,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"All series of Convertible Preferred Stock automatically converted into the Issuer's Common Stock on a 7.180193-for-1 basis upon on November 21, 2017 and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"All series of Convertible Preferred Stock automatically converted into the Issuer's Common Stock on a 7.180193-for-1 basis upon on November 21, 2017 and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"All series of Convertible Preferred Stock automatically converted into the Issuer's Common Stock on a 7.180193-for-1 basis upon on November 21, 2017 and had no expiration date."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F3","text":"All series of Convertible Preferred Stock automatically converted into the Issuer's Common Stock on a 7.180193-for-1 basis upon on November 21, 2017 and had no expiration date."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1544858},"source":{"system":"sec-edgar","filing":"0000899243-17-027197","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1604950/000089924317027197/doc4.xml","form_type":"4"}},{"id":4154341,"issuer":{"id":74456,"kind":"organization","name":"scPharmaceuticals Inc.","symbol":"SCPH"},"owners":[{"id":108415,"kind":"person","name":"Lundbeckfond Invest A/S","position":1,"cik":"0001591046","reported_name":"Lundbeckfond Invest A/S","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2017-11-21T19:24:34.000Z","date":"2017-11-21","kind":"purchase","acquired":true,"shares":654762,"price":14,"value":9166668.0,"ownership":{"direct":true},"balance_after":3183986,"source":{"system":"sec-edgar","filing":"0000899243-17-027197","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1604950/000089924317027197/doc4.xml","form_type":"4"}},{"id":4154340,"issuer":{"id":74456,"kind":"organization","name":"scPharmaceuticals Inc.","symbol":"SCPH"},"owners":[{"id":108415,"kind":"person","name":"Lundbeckfond Invest A/S","position":1,"cik":"0001591046","reported_name":"Lundbeckfond Invest A/S","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2017-11-21T19:24:34.000Z","date":"2017-11-21","kind":"exercise","acquired":true,"shares":984366,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents the total number of shares of Common Stock received by the Reporting Person  upon conversion of the Issuer's Series B Preferred Stock in connection with the closing of the Issuer's initial public offering."}],"balance_after":2529224,"source":{"system":"sec-edgar","filing":"0000899243-17-027197","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1604950/000089924317027197/doc4.xml","form_type":"4"}},{"id":4154339,"issuer":{"id":74456,"kind":"organization","name":"scPharmaceuticals Inc.","symbol":"SCPH"},"owners":[{"id":108415,"kind":"person","name":"Lundbeckfond Invest A/S","position":1,"cik":"0001591046","reported_name":"Lundbeckfond Invest A/S","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2017-11-21T19:24:34.000Z","date":"2017-11-21","kind":"exercise","acquired":true,"shares":1544858,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents the total number of shares of Common Stock received by the Reporting Person  upon conversion of the Issuer's Series A Preferred Stock in connection with the closing of the Issuer's initial public offering."}],"balance_after":1544858,"source":{"system":"sec-edgar","filing":"0000899243-17-027197","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1604950/000089924317027197/doc4.xml","form_type":"4"}}]}